Bacteriophage salmonellezny A, B, C, D, E groups
Producer: Federal state unitary enterprise NPO Mikrogen Russia
Code of automatic telephone exchange: V03A
Pharm group: a href="javascript:if(confirm(%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57 \n\nThis file was not retrieved by Teleport Pro, because it is linked too far away from its Starting Address. If you increase the in-domain depth setting for the Starting Address, this file will be queued for retrieval. \n\nDo you want to open it from the server?%27))window.location=%27medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57%27" tppabs="medicalmeds.eu/preparats_title.php?name=-1&mnn=-1&atc=57">Other different drugs
Release form: Firm dosage forms. Tablets.
General characteristics. Structure:
Active ingredient: 72 mg of bacteriophages of the salmonellezny A, B, C, D, E groups (the lyophilized concentrate of a filtrate of a fagolizat of the most widespread salmonellas: гр. A-Salmonella paratyphi A; гр. B-S. paratyphi B, S. typhimurium, S. heidelberg; гр. C-S. newport, S. choleraesuis, S. oranienburg, S. infantis; гр. D-S. dublin, S. enteritidis; гр. E-S. anatum, S. newlands).
Excipients: pectin, calcium a gluconate monohydrate, Dextrosums the monohydrate, talc purified calcium stearate.
Pharmacological properties:
Pharmacodynamics. Drug causes a specific lysis of salmonellas of group A - Salmonella paratyphi A; groups B - Salmonella paratyphi B, Salmonella typhimurium, Salmonella heidelberg; groups C - Salmonella newport, Salmonella choleraesuis, Salmonella oranienburg, Salmonella infantis; groups D - Salmonella dublin, Salmonella enteritidis; groups E - Salmonella analum, Salmonella newlands.
Indications to use:
— treatment and prevention of the diseases and a bacteriocarrier caused by salmonellas.
Route of administration and doses:
Treatment and prevention of salmonelloses at adults and children since one year. An important condition zffeknivnoy phagotherapies is preliminary definition of a phagosensitivity of the activator and early use of drug.
For treatment drug is taken by 3 times a day for 1 h before meal from the first day of a disease within 7 - 10 days. At the disease which is characterized by a slight kolitichesky syndrome and in the period of reconvalescence along with reception of tablets it is inside recommended to enter rektalno a liquid bacteriophage, in the form of enemas after bowel emptying instead of 1 reception through a mouth (see the Application instruction of the Bacteriophage of salmonellezny solution of the ABCDE groups for intake and topical administration).
The recommended drug dosages:
img src="http://medicalmeds.eu/img/data:image/png;base64,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" alt="" />
In the preventive purposes drug is recommended to be used for the prevention of a bacteriocarrier, an intrahospital infection, during group diseases in organized collectives and families. Optimum schemes of use - daily reception of a single age dose. Duration of administration of drug is defined by epidemiological situation conditions.
Features of use:
Use at pregnancy and feeding by a breast. Use of drug in the presence of the infections caused by fagochuvstvitelny strains is reasonable (according to the recommendation of the doctor).
Use for children. Contraindicated to children till 1 year.
Special instructions. Influence on ability to driving of motor transport and to control of mechanisms. It is not established.
Side effects:
Are noted.
Interaction with other medicines:
Use is possible in combination with other medicines, including with antibiotics.
Contraindications:
- age till 1 year.
Overdose:
It is not established.
Storage conditions:
Drug is stored according to the joint venture 3.3.2.1248-03 in dry, protected from light and the place, unavailable to children, at a temperature from 2 °C to 8 °C. A period of validity - 2 years.
Issue conditions:
Without recipe
Packaging:
50 pieces - bottles (10) - packs cardboard.